These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 10336580

  • 41. Enantioselective HPLC analysis of propafenone and of its main metabolites using polysaccharide and protein-based chiral stationary phases.
    Bonato PS, de Abreu LR, de Gaitani CM, Lanchote VL, Bertucci C.
    Biomed Chromatogr; 2000 Jun; 14(4):227-33. PubMed ID: 10861733
    [Abstract] [Full Text] [Related]

  • 42. [A reversed phase HPLC method with pre-column derivatization to determine propafenone enantiomers in human plasma].
    Wang Y, Zhong D, Chen R.
    Yao Xue Xue Bao; 1998 Jun; 33(2):138-42. PubMed ID: 11938950
    [Abstract] [Full Text] [Related]

  • 43. [Pharmacogenetic study of the response to flecainide and propafenone in patients with atrial fibrillation].
    Martínez-Sellés M, Castillo I, Montenegro P, Martín ML, Almendral J, Sanjurjo M.
    Rev Esp Cardiol; 2005 Jun; 58(6):745-8. PubMed ID: 15970126
    [Abstract] [Full Text] [Related]

  • 44. In vitro assessment of various cytochromes P450 and glucuronosyltransferases using the antiarrhythmic propafenone as a probe drug.
    Kroemer HK, Botsch S, Heinkele G, Schick M.
    Methods Enzymol; 1996 Jun; 272():99-105. PubMed ID: 8791766
    [No Abstract] [Full Text] [Related]

  • 45. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
    Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lötsch J, Roots I, Brockmöller J.
    Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
    [Abstract] [Full Text] [Related]

  • 46. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
    Dorne JL, Walton K, Slob W, Renwick AG.
    Food Chem Toxicol; 2002 Nov; 40(11):1633-56. PubMed ID: 12176090
    [Abstract] [Full Text] [Related]

  • 47. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.
    Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, Woosley RL.
    Circulation; 1987 Apr; 75(4):785-91. PubMed ID: 3829342
    [Abstract] [Full Text] [Related]

  • 48. [The bioequivalence of two oral propafenone preparations].
    Koytchev R, Alken RG, Mayer O, Böhm R, Ellrich A, Waldner-Kölblin RG.
    Arzneimittelforschung; 1995 May; 45(5):542-5. PubMed ID: 7612052
    [Abstract] [Full Text] [Related]

  • 49. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
    Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI.
    J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
    [Abstract] [Full Text] [Related]

  • 50. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate.
    Seeringer A, Brockmöller J, Bauer S, Kirchheiner J.
    Eur J Clin Pharmacol; 2008 Sep; 64(9):883-8. PubMed ID: 18545991
    [Abstract] [Full Text] [Related]

  • 51. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
    Belmonte C, Ochoa D, Román M, Saiz-Rodríguez M, Wojnicz A, Gómez-Sánchez CI, Martín-Vílchez S, Abad-Santos F.
    Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
    [Abstract] [Full Text] [Related]

  • 52. Comparative bioavailability of propafenone after administration of a magistral suspension vs. commercial tablets in healthy volunteers.
    Juárez Olguín H, Flores Pérez C, Ramírez Mendiola B, Barranco Garduño L, Sandoval Ramírez E, Flores Pérez J.
    Arzneimittelforschung; 2009 Jun; 59(3):117-20. PubMed ID: 19402341
    [Abstract] [Full Text] [Related]

  • 53. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.
    Giessmann T, Modess C, Hecker U, Zschiesche M, Dazert P, Kunert-Keil C, Warzok R, Engel G, Weitschies W, Cascorbi I, Kroemer HK, Siegmund W.
    Clin Pharmacol Ther; 2004 Mar; 75(3):213-22. PubMed ID: 15001973
    [Abstract] [Full Text] [Related]

  • 54. The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine.
    Yasuda SU, Zannikos P, Young AE, Fried KM, Wainer IW, Woosley RL.
    Br J Clin Pharmacol; 2002 May; 53(5):519-25. PubMed ID: 11994058
    [Abstract] [Full Text] [Related]

  • 55. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
    Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA.
    Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
    [Abstract] [Full Text] [Related]

  • 56. Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population.
    Sunthankar SD, Kannankeril PJ, Gaedigk A, Radbill AE, Fish FA, Van Driest SL.
    Clin Transl Sci; 2022 Jul; 15(7):1787-1795. PubMed ID: 35514162
    [Abstract] [Full Text] [Related]

  • 57. Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers.
    Pawlowska M, Bogiel M, Duda J, Sieradzki E.
    Eur J Clin Pharmacol; 2015 Jun; 71(6):699-705. PubMed ID: 25953735
    [Abstract] [Full Text] [Related]

  • 58. Novel sustained-release of propafenone through pellets: preparation and in vitro/in vivo evaluation.
    Zhang L, Jiang P, Liu J.
    Int J Mol Sci; 2014 Sep 02; 15(9):15503-11. PubMed ID: 25184949
    [Abstract] [Full Text] [Related]

  • 59. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.
    Jurica J, Bartecek R, Zourkova A, Pindurova E, Sulcova A, Kasparek T, Zendulka O.
    J Clin Pharm Ther; 2012 Aug 02; 37(4):486-90. PubMed ID: 22548589
    [Abstract] [Full Text] [Related]

  • 60. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
    Hou ZY, Chen CP, Yang WC, Lai MD, Buchert ET, Chung HM, Pickle LW, Woosley RL.
    Clin Pharmacol Ther; 1996 Apr 02; 59(4):411-7. PubMed ID: 8612385
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.